Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

LG Energy Solution / Equity Capital Markets

<ul>
<li>In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, specifically for India, Asia-linked ADRs, Korea, Japan and ASEAN.</li>
<li>This list has been compiled on a best effort basis from tracking the company filings and through various other sources.</li>
<li>The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.</li>
</ul>


In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, specifically for India, Asia-linked ADRs, Korea, Japan and ASEAN.
This list has been compiled on a best effort basis from tracking the company filings and through various other sources.
The deals you see in this note are only a part of our full IPO pipeline tracker. Feel free to drop us a message for additional information on these IPOs.


Aequitas 2023 Asia IPO Pipeline - India, ADRs, Korea, Japan and ASEAN

APAC IPOs & Placements, Aequitas Research

Ethan Aw

APAC IPOs & Placements

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mankind-pharma-ltd" target="_blank" data-smartkarma-citation="entities:36389:1" rel="noopener">Mankind Pharma Ltd (6596876Z IN)</a> is looking to raise about US$1bn in its upcoming India IPO. The deal will be run by Kotak, Axis Capital, IIFL Securities, Jefferies and JPM. </li>
<li>Mankind Pharma (MK) is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various therapeutic areas, as well as several consumer healthcare products. </li>
<li>It is mainly focused on the domestic market. 18 of its brands were among the 300 highest selling brands in the Indian Pharmaceutical Market (IPM), according to IQVIA.</li>
</ul>



Mankind Pharma Ltd (6596876Z IN) is looking to raise about US$1bn in its upcoming India IPO. The deal will be run by Kotak, Axis Capital, IIFL Securities, Jefferies and JPM. 
Mankind Pharma (MK) is a pharmaceutical company engaged in developing, manufacturing and marketing a range of pharmaceutical formulations across various therapeutic areas, as well as several consumer healthcare products. 
It is mainly focused on the domestic market. 18 of its brands were among the 300 highest selling brands in the Indian Pharmaceutical Market (IPM), according to IQVIA.


India

Mankind Pharma Limited is a pharmaceutical company. The Company focuses developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. Mankind Pharma serves customers in India.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Mankind Pharma (MANKIND IN)

Aequitas 2023 Asia IPO Pipeline - India, ADRs, Korea, Japan and ASEAN

In this note, we will take a look at the Asia Pacific IPO pipeline for 2023, specifically for India, Asia-linked ADRs, Korea, Japan and ASEAN.

Sumeet Singh

Mankind Pharma Pre-IPO Tearsheet

Mankind Pharma Ltd (6596876Z IN) is looking to raise about US$1bn in its upcoming India IPO. The deal will be run by Kotak, Axis Capital, IIFL...

Ethan Aw

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)